Stock listing

NASDAQ:CLYM Climb Bio, Inc. Stock

Home listing (NASDAQ) of Climb Bio, Inc.

Follow Climb Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CLYM

$9.19 USD -0.11 (-1.2%)

Close on Nov 20, 2026

Past year +431.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.90 – $9.40 USDNov 20, 2026
Volume
770,170 sharesNov 20, 2026
Market cap
$539.8M USDAt the close on Nov 20, 2026 · price × 58.74M shares outstanding
52-week range
$1.64 – $18.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.07M USDMedian day 1.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Climb Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CLYM · Home$9.19 USD-0.11 (-1.2%)770,170$8.94$9.398$8.90$9.30Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLYM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$9.19-0.11-1.2%$8.94$9.398$8.90770,170
$9.30-0.48-4.9%$9.79$9.995$9.24865,210
$9.78-0.16-1.6%$9.95$10.42$9.37593,757
$9.94-0.42-4.1%$10.10$10.57$9.87675,561
$10.36-0.51-4.7%$10.76$10.99$10.19667,579
$10.87-1.38-11.3%$11.97$12.14$10.681,346,255
$12.25+0.51+4.3%$11.72$12.44$11.491,663,783
$11.74+0.73+6.6%$10.96$11.87$10.621,567,746
$11.01+0.72+7.0%$10.50$11.54$10.281,783,649
$10.29+1.42+16.0%$9.05$10.33$8.841,139,760
$8.87-0.46-4.9%$8.87$9.20$8.4851,435,446
$9.33-0.42-4.3%$9.97$10.10$9.1911,044,046
$9.75+0.01+0.1%$9.86$10.07$9.56887,621
$9.74-0.51-5.0%$10.25$10.44$9.691,146,907
$10.25-0.08-0.8%$10.29$10.51$10.02708,718
$10.33+0.21+2.1%$10.35$10.55$10.09688,967
$10.12+0.55+5.7%$9.32$10.13$9.25944,697
$9.57+0.76+8.6%$8.90$10.15$8.8153,904,200
$8.81-1.38-13.5%$9.88$9.99$8.703,381,116
$10.19-0.35-3.3%$10.47$10.66$10.05495,694
$10.54-0.33-3.0%$10.57$11.23$10.44654,057
$10.87+0.07+0.6%$10.83$11.26$10.60930,385
$10.80+1.07+11.0%$9.84$10.99$9.841,369,064
$9.73-0.09-0.9%$9.92$10.43$9.611,214,409
$9.82-1.09-10.0%$10.89$10.91$9.69990,300
$10.91+0.62+6.0%$10.32$10.98$10.25515,500
$10.29-0.02-0.2%$10.19$10.64$10.09987,700
$10.31-0.52-4.8%$10.75$10.79$10.18901,300
$10.83-0.17-1.5%$10.91$11.15$10.73911,600
$11.00+0.14+1.3%$10.81$11.30$10.75638,000
$10.86+0.15+1.4%$10.55$11.00$10.271,148,800
$10.71+0.03+0.3%$10.43$10.95$10.34755,800
$10.68-0.37-3.3%$11.12$11.25$10.64953,600
$11.05+0.11+1.0%$10.94$11.20$10.701,206,400
$10.94-0.13-1.2%$11.29$11.29$10.731,574,900
$11.07-0.40-3.5%$11.39$11.67$11.03953,000
$11.47-0.03-0.3%$11.69$11.93$11.321,411,200
$11.50-0.24-2.0%$11.79$11.81$11.311,140,400
$11.74+0.08+0.7%$11.57$11.93$11.39811,000
$11.66-0.23-1.9%$11.89$11.92$11.531,532,900
$11.89-0.63-5.0%$12.35$12.42$11.381,871,600
$12.52-1.69-11.9%$14.29$14.39$12.062,140,800
$14.21+0.57+4.2%$13.75$14.29$13.63930,000
$13.64-0.41-2.9%$14.13$14.23$13.551,222,200
$14.05-0.01-0.1%$14.15$14.44$13.924,049,700
$14.06-0.05-0.4%$14.49$14.66$13.771,401,600
$14.11+0.20+1.4%$14.00$14.55$13.872,622,000
$13.91-0.65-4.5%$14.71$14.71$13.381,552,500
$14.56+0.31+2.2%$14.49$14.96$14.301,094,900
$14.25-0.70-4.7%$15.21$15.45$14.091,378,200
$14.95-0.10-0.7%$14.83$15.07$14.161,494,600
$15.05-0.85-5.3%$15.82$16.17$14.961,633,100
$15.90+0.38+2.4%$15.62$16.08$15.13918,200
$15.52+0.93+6.4%$14.49$15.96$14.281,495,300
$14.59-0.46-3.1%$13.96$15.39$13.605,527,000
$15.05+0.23+1.6%$14.79$15.29$14.402,214,700
$14.82+1.09+7.9%$13.88$15.03$13.091,972,500
$13.73-0.84-5.8%$14.58$14.70$13.491,437,100
$14.57-0.49-3.3%$14.86$15.13$14.37840,700
$15.06-1.02-6.3%$16.09$16.33$14.941,552,500
$16.08-1.76-9.9%$17.72$17.80$16.011,392,100
$17.84+1.44+8.8%$16.75$18.33$16.751,203,100
$16.40-0.88-5.1%$17.27$17.41$16.051,177,800
$17.28+0.26+1.5%$17.26$17.71$17.00957,400
$17.02-0.32-1.8%$17.16$17.45$16.72903,900
Ticker
NASDAQ:CLYM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Climb Bio, Inc. news

Climb Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 44 in all · newest Nov 5, 2026 · oldest 2024
Decks
12 decks · latest Nov 5, 2026

Where Climb Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CLYM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CLYMBOATSUnited StatesUSD

Valuation

Price/book 2.4× against a median of 1.6×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$335.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.44

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.4M14.6×4.5×22.9×2.6×28.0%0.8×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
ArriVent BioPharma, Inc. · NASDAQ:AVBPUS$544.1MUS$151.2Mn/a30.2×n/a1.4×n/a0.0×1.18
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.7Mn/an/an/a1.6×n/a0.2×n/a
Alumis Inc. · NASDAQ:ALMSUS$512.6MUS$116.5Mn/a16.1×n/a1.4×n/a0.1×1.58
Electra Therapeutics, Inc. · NASDAQ:ETRAUS$509.8MUS$107.3Mn/an/an/a1.3×n/a0.0×n/a
Median of the othersUS$544.9MUS$230.5M14.6×30.2×22.9×1.6×−90.3%0.0×1.50

Forecasts

14 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
28.40 USD · Analysts' mean
EPS, year to Dec 2026
-0.75 · 10 analysts

Team and board

Officers

OfficerRole
Aoife BrennanBoard Member, President and Chief Executive Officer
Susan AltschullerChief Financial Officer
Chandra AdamsSenior Vice President, General Counsel
Adam VillaSenior Vice President, Technical Operations
Ashley JonesSenior Vice President, People & Workforce Strategy
Edgar CharlesChief Medical Officer
Perrin WilsonChief Business Officer

Board

DirectorRole
Douglas E. WilliamsChairman
Aoife BrennanBoard Member, President and Chief Executive Officer
Bo CumboBoard Member
Breanna O’ReillyBoard Member
Judith DunnBoard Member
Kim Cobleigh DrapkinBoard Member
Stephen ThomasBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−4.9%
Q2 2026Aug 6, 2026 · Before open+12.3%
Q1 2026May 7, 2026 · Before open−2.5%
Q4 2025Mar 9, 2026+2.1%
Q3 2025Nov 6, 2025 · Before open+1.6%
Q2 2025Aug 14, 2025 · Before open+5.5%
Q1 2025May 14, 2025−5.5%
Q4 2024Mar 25, 2025 · After close0.0%
Q3 2024Nov 12, 2024−13.1%
Q2 2024Aug 14, 2024−2.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024−3.2%
Q4 2023Mar 4, 2024+4.8%
Q3 2023Nov 6, 2023−1.6%
Q2 2023Sep 11, 2023+2.3%
Q1 2023May 11, 2023 · After close−4.2%
Q4 2022Mar 6, 2023+3.2%
Q3 2022Nov 14, 2022 · Before open−3.3%
Q2 2022Aug 15, 2022 · Before open−2.0%
Q1 2022May 16, 2022−11.1%
Q4 2021Mar 7, 2022 · After close+1.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck60 slidesNov 5, 2026
Investor Presentation (October 2026)Investor deck59 slidesOct 26, 2026
Technical Presentation (September 2026)Technical26 slidesSep 3, 2026
Investor Presentation (September 2026)Investor deck57 slidesSeptember 2026
Technical Presentation (May 2026)Technical51 slidesMay 5, 2026
Technical Presentation (September 2025)Technical46 slidesSep 29, 2025
Eliem Therapeutics — Merger or Acquisition (April 2024)Merger or acquisition18 slidesApr 11, 2024
Eliem Therapeutics — Investor Presentation (May 2023)Investor deck20 slidesMay 11, 2023
Eliem Therapeutics — Investor Presentation (November 2022)Investor deck33 slidesNov 14, 2022
Eliem Therapeutics — Investor Presentation (October 2022)Investor deck24 slidesOct 5, 2022
All 12 decks
DeckKindSlidesDate
Eliem Therapeutics — Investor Presentation (March 2022)Investor deck34 slidesMar 29, 2022
Eliem Therapeutics — Investor Presentation (November 2021)Investor deck29 slidesNov 8, 2021

Open Decks

Financings

RaiseDate
Private placement of shares of common stock and pre-funded warrants
Announced: about US$110M · US$9.5 a share · Leerink Partners +5
Dealers: Leerink Partners (lead), Piper Sandler (lead), Raymond James, BTIG, Baird, H.C. Wainwright & Co.
Buyers: Adage Capital Partners, L.P.; ADAR1 Capital Management; Affinity Asset Advisors, LLC; Ally Bridge Group; Cormorant Asset Management; Driehaus Capital Management; Great Point Partners, LLC; RA Capital Management; Redmile; Sirenia Capital Management LP; Woodline Partners LP
Apr 28, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Eliem Therapeutics, Inc. Priced at US$12.50 a share on Aug 9, 2021.

Price
US$12.50 a share
Shares offered
6,400,000 shares of common stock
Offering size
US$80 million
Underwriters' option
Up to 960,000 more shares
Underwriters
SVB Leerink, Evercore ISI, Stifel, Guggenheim Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 12, 2021
Filed publiclyJul 16, 2021
Amended 4 timesNewest Aug 9, 2021
Shares registered with an exchangeAug 3, 2021
Declared effective by the SECAug 9, 2021
Final prospectus, with the priceAug 11, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Aug 11, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000000
Cost of revenue97.0K
Gross profit-97.0K
Research and development46.7M14.3M15.4M26.2M23.3M8.77M4.02M
Selling, general and administrative21.2M16.0M24.9M18.9M12.3M2.42M677.0K
Operating income-67.9M-82.0M-40.3M-45.1M-35.7M-20.9M-7.45M
Depreciation and amortization97.0K0
EBITDA-67.8M-82.0M
Income before tax-59.9M-73.9M-35.1M-45.2M-47.5M-20.7M-6.55M
Income tax000000
Net income-59.9M-73.9M-35.1M-45.2M-47.5M-20.7M-6.55M
Earnings per share, basic-0.88-1.53-1.30-1.72-4.24-10.49-0.56
Earnings per share, diluted-0.88-1.53-1.30-1.72-4.24-10.49

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents35.7M87.2M93.1M43.6M46.9M20.5M21.2M
Short-term investments65.4M63.7M13.7M80.0M89.6M0
Receivables1.12M2.46M6.49M6.52M
Current assets105.8M154.9M110.3M134.4M148.3M22.0M21.3M
Property, plant and equipment288.0K199.0K
Total assets167.7M217.2M110.5M135.0M173.2M24.6M21.4M
Accounts payable2.27M705.0K66.0K750.0K1.40M1.09M647.0K
Current liabilities6.98M4.93M2.83M6.10M6.03M3.06M783.0K
Total debt541.0K532.0K349.0K480.0K
Total liabilities7.27M5.31M2.87M6.28M6.04M3.06M783.0K
Shareholders' equity160.5M211.9M107.6M128.7M167.2M-25.0M20.6M
Shares outstanding47.8M67.3M27.7M26.6M26.6M3.42M11.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-54.4M-15.6M-20.6M-37.4M-36.1M-14.1M-5.01M
Capital spending-186.0K000000
Free cash flow-54.5M-15.6M-20.6M-37.4M-36.1M-14.1M-5.01M
Cash from investing2.83M-121.1M69.0M34.4M-115.0M8.08M
Cash from financing-21.0K130.7M841.0K0177.2M4.92M26.2M
Change in cash-51.5M-5.88M49.5M-3.34M26.4M-736.0K21.2M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 9, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 5, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 23, 2026Current reportSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 17, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
8-K · Current reportSep 3, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 14, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 7, 2026Big-stake noticeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 1, 2026Insider tradeSEC
8-K · Current reportJul 1, 2026Management or board changeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
8-K · Current reportJun 12, 2026Material contractSEC
424B5 · ProspectusJun 12, 2026Offer documentSEC
8-K · Current reportJun 11, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJun 10, 2026Other filingsSEC
424B3 · ProspectusJun 9, 2026Offer documentSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Management or board changeSEC
CORRESP · Letter to the SECJun 5, 2026Other filingsSEC
8-K · Current reportJun 5, 2026Current reportSEC
UPLOAD · Letter from the SECJun 4, 2026Other filingsSEC
S-3 · Registration statementMay 29, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
8-K · Current reportMay 5, 2026Current reportSEC
DMay 4, 2026Other filingsSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 29, 2026Big-stake noticeSEC
8-K · Current reportApr 28, 2026Material contractSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
8-K · Current reportApr 3, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 12, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
8-K · Current reportDec 31, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 15, 2025Big-stake noticeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
8-K · Current reportDec 11, 2025Material contractSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 17, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 16, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2025Insider tradeSEC
8-K · Current reportOct 1, 2025Management or board changeSEC
8-K · Current reportSep 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Management or board changeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 23, 2025Management or board changeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2025Insider tradeSEC
S-8 · Registration statement for employee plansApr 1, 2025Offer documentSEC
8-K · Current reportApr 1, 2025Management or board changeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
8-K · Current reportMar 25, 2025ResultsSEC
424B5 · ProspectusMar 25, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025ResultsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
CORRESP · Letter to the SECNov 20, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 19, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2024Insider tradeSEC
S-3 · Registration statementNov 12, 2024Offer documentSEC
8-K · Current reportNov 12, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportOct 15, 2024ResultsSEC
8-K · Current reportOct 2, 2024Current reportSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
8-K · Current reportAug 27, 2024Management or board changeSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 26, 2024Insider tradeSEC
8-K · Current reportAug 26, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedAug 16, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJul 24, 2024Other filingsSEC
4 · Change in ownershipJul 23, 2024Insider tradeSEC
424B3 · ProspectusJul 23, 2024Offer documentSEC
CORRESP · Letter to the SECJul 19, 2024Other filingsSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
UPLOAD · Letter from the SECJul 18, 2024Other filingsSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
S-3 · Registration statementJul 12, 2024Offer documentSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJul 9, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
DJul 2, 2024Other filingsSEC
DJul 2, 2024Other filingsSEC
SC 13G · Big-stake noticeJul 2, 2024Big-stake noticeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 1, 2024Big-stake noticeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 27, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 27, 2024Insider tradeSEC
8-K · Current reportJun 27, 2024Acquisition or disposalSEC
8-K · Current reportJun 26, 2024Meeting outcomeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
DEFA14A · Additional proxy materialJun 14, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialJun 12, 2024Meeting noticeSEC
8-K · Current reportJun 12, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedJun 6, 2024Big-stake noticeSEC
ARS · Annual report to shareholdersJun 4, 2024Annual reportSEC
DEFM14AJun 4, 2024Meeting noticeSEC
PREM14AMay 17, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMay 17, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMay 17, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
SC 13G · Big-stake noticeMay 7, 2024Big-stake noticeSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedApr 12, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 11, 2024Meeting noticeSEC
8-K · Current reportApr 11, 2024Material contractSEC
4 · Change in ownershipApr 8, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
8-K · Current reportMar 18, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 18, 2024Big-stake noticeSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 17, 2023Big-stake noticeSEC

This page holds 200 of 326 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Climb Bio, Inc.’s releases · as of Oct 30, 2026

Common shares
58,738,178
Fully diluted
58,738,178

Fully diluted

LineSharesAs of
Common shares58,738,178Oct 30, 2026

Share count over time

CountShares
Oct 30, 202658,738,178

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Ra Capital Management, L.P.10.1MUS$116MSep 30, 2026
Fidelity9.27MUS$106MSep 30, 2026
UBS4.49MUS$51.5MSep 30, 2026
Vanguard3.2MUS$36.7MSep 30, 2026
BlackRock2.94MUS$33.7MSep 30, 2026
Braidwell LP2.86MUS$32.8MSep 30, 2026
Woodline Partners LP2.73MUS$31.3MSep 30, 2026
T. Rowe Price2.42MUS$27.8MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.17MUS$24.9MSep 30, 2026
Cormorant Asset Management, LP2.11MUS$24.2MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Frontier Capital Management Co LLC2.09MUS$24MSep 30, 2026
State Street1.85MUS$21.2MSep 30, 2026
Morgan Stanley1.12MUS$12.9MSep 30, 2026
Ameriprise995KUS$11.4MSep 30, 2026
Redmile Group, LLC974KUS$11.2MSep 30, 2026
Affinity Asset Advisors, LLC972KUS$11.1MSep 30, 2026
Geode Capital951KUS$10.9MSep 30, 2026
Superstring Capital Management LP918KUS$10.5MSep 30, 2026
Great Point Partners LLC800KUS$9.18MSep 30, 2026
ADAR1 Capital Management, LLC793KUS$9.09MSep 30, 2026
Driehaus Capital Management LLC790KUS$9.06MSep 30, 2026
Eventide Asset Management, LLC730KUS$8.37MSep 30, 2026
Integral Health Asset Management, LLC700KUS$8.03MSep 30, 2026
Marshall Wace, LLP559KUS$6.41MSep 30, 2026
Goldman Sachs529KUS$6.06MSep 30, 2026
Parkman Healthcare Partners LLC468KUS$5.37MSep 30, 2026
Citadel453KUS$5.19MSep 30, 2026
Sphera Funds Management LTD.417KUS$4.78MSep 30, 2026
Dimensional402KUS$4.61MSep 30, 2026
Nan Fung Trinity (Hk) LTD361KUS$4.14MSep 30, 2026
Northern Trust359KUS$4.11MSep 30, 2026
Schwab346KUS$3.97MSep 30, 2026
Jane Street317KUS$3.63MSep 30, 2026
TD304KUS$3.49MSep 30, 2026
Jefferies Financial Group Inc.291KUS$3.34MSep 30, 2026
Squarepoint Ops LLC254KUS$2.91MSep 30, 2026
Prudential Financial Inc236KUS$2.71MSep 30, 2026
Boothbay Fund Management, LLC208KUS$2.39MSep 30, 2026
Two Sigma188KUS$2.16MSep 30, 2026
Fifth Third Bancorp182KUS$2.08MSep 30, 2026
Manufacturers Life Insurance Company, The181KUS$2.08MSep 30, 2026
XTX Topco Ltd161KUS$1.84MSep 30, 2026
LPL Financial LLC157KUS$1.8MSep 30, 2026
BNY135KUS$1.55MSep 30, 2026
ArchPoint Investors133KUS$1.52MSep 30, 2026
Raymond James Financial Inc130KUS$1.49MSep 30, 2026
Wellington126KUS$1.45MSep 30, 2026
Rock Springs Capital Management LP116KUS$1.34MSep 30, 2026
D. E. Shaw & Co., Inc.110KUS$1.26MSep 30, 2026
Millennium105KUS$1.2MSep 30, 2026

This page holds 50 of 124 holders. Open Shareholders

Funds

HolderSharesValueAs of
Fidelity Small Cap Growth Fund1.88MUS$22.4MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.64MUS$21.3MJun 30, 2026
Fidelity Stock Selector Small Cap Fund1.53MUS$18.2MJul 31, 2026
Vanguard Total Stock Market Index Fund1.37MUS$17.8MJun 30, 2026
Fidelity Advisor Biotechnology Fund996KUS$11.9MJul 31, 2026
Fidelity Small Cap Growth K6 Fund978KUS$11.6MJul 31, 2026
iShares Russell 2000 ETF891KUS$11.6MJun 30, 2026
Fidelity Series Small Cap Opportunities Fund876KUS$10.4MJul 31, 2026
Columbia Small Cap Growth Fund538KUS$5.89MMay 31, 2026
Fidelity Small Cap Index Fund386KUS$4.59MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Extended Market Index Fund292KUS$3.81MJun 30, 2026
Fidelity Advisor Health Care Fund214KUS$2.55MJul 31, 2026
iShares Russell 2000 Value ETF180KUS$2.35MJun 30, 2026
iShares Russell 2000 Growth ETF142KUS$1.85MJun 30, 2026
Fidelity Small Cap Stock Fund138KUS$1.65MJul 31, 2026
Fidelity Extended Market Index Fund134KUS$1.47MMay 31, 2026
Fidelity Fundamental Small-Mid Cap ETF133KUS$1.59MJul 31, 2026
iShares Micro-Cap ETF118KUS$1.54MJun 30, 2026
T. Rowe Price Health Sciences Portfolio103KUS$1.34MJun 30, 2026
Schwab Small-Cap Index Fund85,579US$1.02MJul 31, 2026
Dimensional U.S. Small Cap ETF76,929US$915KJul 31, 2026
Cambria Value and Momentum ETF76,753US$913KJul 31, 2026
Ultra-Small Company Market Fund73,800US$962KJun 30, 2026
Master Small Cap Index Series64,184US$837KJun 30, 2026
U.S. Micro Cap Portfolio59,637US$710KJul 31, 2026
AMG Frontier Small Cap Growth Fund56,115US$668KJul 31, 2026
Ultra-Small Company Fund50,000US$652KJun 30, 2026
Fidelity Total Market Index Fund46,916US$514KMay 31, 2026
Nuveen Small Cap Blend Index Fund46,707US$556KJul 31, 2026
Fidelity Series Total Market Index Fund39,283US$431KMay 31, 2026
EQ/2000 Managed Volatility Portfolio37,315US$487KJun 30, 2026
Columbia Variable Portfolio - Small Company Growth Fund36,639US$478KJun 30, 2026
Health Sciences Trust36,100US$471KJun 30, 2026
PGIM Quant Solutions Small-Cap Value Fund32,100US$382KJul 31, 2026
Nuveen Equity Index Fund31,028US$369KJul 31, 2026
U.S. Small Cap Portfolio30,469US$363KJul 31, 2026
Avantis U.S. Small Cap Equity ETF30,387US$333KMay 31, 2026
Fidelity Nasdaq Composite Index Fund29,677US$325KMay 31, 2026
Fidelity Small Cap Value Index Fund27,692US$361KJun 30, 2026
Virtus Biotech Clinical Trials Etf27,171US$323KJul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio25,624US$334KJun 30, 2026
LVIP State Street Small-Cap Index Fund25,500US$333KJun 30, 2026
Schwab Total Stock Market Index Fund22,000US$262KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund20,426US$266KJun 30, 2026
Vanguard Balanced Index Fund19,079US$249KJun 30, 2026
Small Cap Index Fund18,118US$236KJun 30, 2026
Global X Russell 2000 ETF16,764US$199KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund16,138US$210KJun 30, 2026
Fidelity Small Cap Growth Index Fund14,597US$190KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF13,817US$164KJul 31, 2026

This page holds 50 of 106 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Thomas Stephen Basil
Director
Sale100,000USD 13.67US$1.37MSep 15, 2026
Brennan Aoife
Director, Officer: President and CEO
Sale30,902USD 13.17US$407KJun 29, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.33.00%23.9MNov 5, 2026Schedule 13D
FMR LLC15.00%8.62MSep 30, 2026Schedule 13G
Pontifax VI G.P. L.P.7.70%5.21MJun 27, 2024Schedule 13G
Deerfield Mgmt, L.P.5.25%3.07MOct 27, 2026Schedule 13G
BlackRock, Inc.5.00%2.9MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Aug 9, 2021
Robert Azelby
Other companies: Tango Therapeutics, Inc. (Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026); Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past)
President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past
Alexander Cumbo
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Vor Biopharma Inc. (Chair of the Compensation Committee · Since at least Jul 16, 2025); Solid Biosciences Inc. (President and CEO, Director · Since at least Dec 2, 2022); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past)
Director · Since at least Mar 28, 2025
Erin Lavelle
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past)
COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past
Leone Patterson
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Director · Since at least Jun 8, 2022); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Feb 15, 2023 – Feb 23, 2024 · Past)
Director · May 19, 2022 – May 19, 2022 · Past
Aoife Brennan
Other companies: Xilio Therapeutics, Inc. (Director · Since at least Jun 13, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past); Synlogic Inc (President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past)
President and CEO, Director · Since at least Jun 27, 2024
Kimberlee C. Drapkin
Other companies: Kineta Inc. (Director · Since at least Jun 23, 2025); LENZ Therapeutics, Inc. (Director · Since at least Jun 11, 2025); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 4, 2025)
Director · Since at least Mar 28, 2025
Bo Cumbo
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Solid Biosciences Inc. (President and CEO · Since at least Jun 2, 2026)
Board Member · Since at least May 14, 2025
Brett Kaplan
Other companies: Compass Therapeutics, Inc. (Director · Sep 10, 2020 – Feb 18, 2022 · Past); Prevail Therapeutics Inc (Chief Financial Officer · Jun 19, 2019 – Jan 22, 2021 · Past)
Chief Operating Officer · Aug 26, 2024 – Jan 13, 2025 · Past
James B. Bucher
Other companies: Zentalis Pharmaceuticals, Inc. (Chief Legal Officer and Corporate Secretary · Since at least Aug 26, 2025); Harpoon Therapeutics Inc (Chief Legal Officer · Dec 21, 2023 – Mar 11, 2024 · Past)
EVP and General Counsel · Oct 31, 2022 – Oct 31, 2022 · Past
All 24 people
PersonSeat
Cindy Driscoll
Other companies: Dianthus Therapeutics, Inc. (See Remarks · Jun 20, 2018 – Oct 1, 2020 · Past)
Senior Vice President, Finance · Since at least Jun 17, 2025
Kim Cobleigh Drapkin
Other companies: Acumen Pharmaceuticals, Inc. (Biotechnology Executive · Since at least Jun 5, 2026)
Board Member · Since at least May 14, 2025
Adam Joseph RosenbergDirector · Aug 9, 2021 – Jun 26, 2024 · Past
Adam VillaSenior Vice President, Technical Operations · Since at least Nov 6, 2025
Ashley JonesSenior Vice President, People & Workforce Strategy · Since at least Nov 6, 2025
Breanna O’ReillyBoard Member · Since at least Aug 6, 2026
Chandra AdamsSenior Vice President, General Counsel · Since at least Nov 5, 2026
Douglas E. WilliamsChairman · Since at least Aug 19, 2025
Edgar CharlesChief Medical Officer · Since at least Jun 11, 2026
Judith DunnBoard Member · Since at least Nov 5, 2026
Perrin WilsonChief Business Officer · Since at least May 14, 2025
Stephen ThomasDirector · Since at least Sep 15, 2026
Susan AltschullerChief Financial Officer · Since at least Nov 6, 2025
Valerie MorissetEVP, R&D AND CSO · Oct 31, 2022 – Jul 19, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Climb Bio, Inc.